Christopher Sarchi Sells 2,218 Shares of Replimune Group, Inc. (NASDAQ:REPL) Stock

Replimune Group, Inc. (NASDAQ:REPL) insider Christopher Sarchi sold 2,218 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $6.47, for a total value of $14,350.46. Following the completion of the sale, the insider now directly owns 92,252 shares of the company’s stock, valued at approximately $596,870.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Replimune Group Price Performance

NASDAQ REPL opened at $5.57 on Wednesday. The company has a quick ratio of 10.72, a current ratio of 10.72 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $342.11 million, a PE ratio of -1.72 and a beta of 1.25. Replimune Group, Inc. has a 12-month low of $5.47 and a 12-month high of $24.81. The company has a 50 day moving average price of $7.16 and a two-hundred day moving average price of $8.19.

Institutional Investors Weigh In On Replimune Group

Several institutional investors and hedge funds have recently modified their holdings of REPL. Mirae Asset Global Investments Co. Ltd. raised its holdings in Replimune Group by 3.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 30,364 shares of the company’s stock valued at $520,000 after buying an additional 1,138 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of Replimune Group by 17.2% during the 3rd quarter. Principal Financial Group Inc. now owns 14,748 shares of the company’s stock worth $252,000 after acquiring an additional 2,165 shares in the last quarter. Barclays PLC increased its holdings in shares of Replimune Group by 4.8% during the 3rd quarter. Barclays PLC now owns 118,412 shares of the company’s stock valued at $2,027,000 after acquiring an additional 5,401 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Replimune Group by 32.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 378,310 shares of the company’s stock valued at $6,473,000 after acquiring an additional 93,364 shares in the last quarter. Finally, Citigroup Inc. lifted its holdings in Replimune Group by 48.7% in the 3rd quarter. Citigroup Inc. now owns 79,527 shares of the company’s stock worth $1,361,000 after purchasing an additional 26,059 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.